224 related articles for article (PubMed ID: 20073086)
1. Analysis of viral clearance unit operations for monoclonal antibodies.
Miesegaes G; Lute S; Brorson K
Biotechnol Bioeng; 2010 Jun; 106(2):238-46. PubMed ID: 20073086
[TBL] [Abstract][Full Text] [Related]
2. Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins.
Brorson K; Krejci S; Lee K; Hamilton E; Stein K; Xu Y
Biotechnol Bioeng; 2003 May; 82(3):321-9. PubMed ID: 12599259
[TBL] [Abstract][Full Text] [Related]
3. Viral clearance using disposable systems in monoclonal antibody commercial downstream processing.
Zhou JX; Solamo F; Hong T; Shearer M; Tressel T
Biotechnol Bioeng; 2008 Jun; 100(3):488-96. PubMed ID: 18438883
[TBL] [Abstract][Full Text] [Related]
4. Generic/matrix evaluation of SV40 clearance by anion exchange chromatography in flow-through mode.
Curtis S; Lee K; Blank GS; Brorson K; Xu Y
Biotechnol Bioeng; 2003 Oct; 84(2):179-86. PubMed ID: 12966574
[TBL] [Abstract][Full Text] [Related]
5. Strategies for developing design spaces for viral clearance by anion exchange chromatography during monoclonal antibody production.
Strauss DM; Cano T; Cai N; Delucchi H; Plancarte M; Coleman D; Blank GS; Chen Q; Yang B
Biotechnol Prog; 2010; 26(3):750-5. PubMed ID: 20306523
[TBL] [Abstract][Full Text] [Related]
6. Anion exchange chromatography provides a robust, predictable process to ensure viral safety of biotechnology products.
Strauss DM; Gorrell J; Plancarte M; Blank GS; Chen Q; Yang B
Biotechnol Bioeng; 2009 Jan; 102(1):168-75. PubMed ID: 18683259
[TBL] [Abstract][Full Text] [Related]
7. The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.
Banton D; Vacante D; Bulthuis B; Goldstein J; Wineburg M; Schreffler J
PDA J Pharm Sci Technol; 2019; 73(6):552-561. PubMed ID: 31101710
[TBL] [Abstract][Full Text] [Related]
8. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
[TBL] [Abstract][Full Text] [Related]
9. Proceedings of the 2017 Viral Clearance Symposium, Session 2.2: DSP Unit Operations-Purification Unit Operations.
Roush D; Kreil TR
PDA J Pharm Sci Technol; 2018; 72(5):479-487. PubMed ID: 30030354
[TBL] [Abstract][Full Text] [Related]
10. Virus filtration of high-concentration monoclonal antibody solutions.
Marques BF; Roush DJ; Göklen KE
Biotechnol Prog; 2009; 25(2):483-91. PubMed ID: 19353736
[TBL] [Abstract][Full Text] [Related]
11. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody capture and viral clearance by cation exchange chromatography.
Miesegaes GR; Lute S; Strauss DM; Read EK; Venkiteshwaran A; Kreuzman A; Shah R; Shamlou P; Chen D; Brorson K
Biotechnol Bioeng; 2012 Aug; 109(8):2048-58. PubMed ID: 22488719
[TBL] [Abstract][Full Text] [Related]
13. Salt tolerant membrane adsorbers for robust impurity clearance.
Riordan WT; Heilmann SM; Brorson K; Seshadri K; Etzel MR
Biotechnol Prog; 2009; 25(6):1695-702. PubMed ID: 19728393
[TBL] [Abstract][Full Text] [Related]
14. Process scale considerations in evaluation studies and scale-up.
Walter JK; Werz W; Berthold W
Dev Biol Stand; 1996; 88():99-108. PubMed ID: 9119169
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of various processing steps for viral clearance of therapeutic proteins: database analyses of commonly used steps.
Cipriano D; Burnham M; Hughes JV
Methods Mol Biol; 2012; 899():277-92. PubMed ID: 22735960
[TBL] [Abstract][Full Text] [Related]
16. Current issues in viral assays and viral clearance evaluation.
Lubiniecki AS
Dev Biol Stand; 1996; 88():9-11. PubMed ID: 9119167
[TBL] [Abstract][Full Text] [Related]
17. Virus elimination during the purification of monoclonal antibodies by column chromatography and additional steps.
Roberts PL
Biotechnol Prog; 2014; 30(6):1341-7. PubMed ID: 25181429
[TBL] [Abstract][Full Text] [Related]
18. Use of bacteriophages as surrogates for mammalian viruses.
McAlister M; Aranha H; Larson R
Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677
[TBL] [Abstract][Full Text] [Related]
19. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
20. Real time quantitative PCR as a method to evaluate xenotropic murine leukemia virus removal during pharmaceutical protein purification.
Shi L; Chen Q; Norling LA; Lau AS; Krejci S; Xu Y
Biotechnol Bioeng; 2004 Sep; 87(7):884-96. PubMed ID: 15334415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
